General Information of Drug (ID: DMFV5UL)

Drug Name
human monoclonal antibodies (GM-CSF) Drug Info
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
TTD Drug ID
DMFV5UL

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Talimogene Laherparepvec DMKBW5C Melanoma 2C30 Approved [2]
Lenzilumab DMSRIT4 Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 Trial [3]
JX-594 DM5WCV4 Hepatocellular carcinoma 2C12.02 Phase 3 [4]
Mavrilimumab DMMVFRC Rheumatoid arthritis FA20 Phase 2 [5]
Cabiralizumab DMGE058 Pancreatic cancer 2C10 Phase 2 [3]
KB002/003 DM60G5O Rheumatoid arthritis FA20 Phase 2 [6]
GSK3196165 DMEXKF4 Rheumatoid arthritis FA20 Phase 2 [5]
KB-003 DM74KIM Severe asthma CA23 Phase 2 [7]
MT203 DM7I0MT Plaque psoriasis EA90.0 Phase 2 [8]
MORAb-022 DMM7TBO Autoimmune diabetes 5A10 Phase 1 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Granulocyte-macrophage colony-stimulating factor (CSF2) TTNYZG2 CSF2_HUMAN Modulator [1]

References

1 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther. 2006 Sep;14(3):361-70.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
7 US patent application no. 2010,0158,905, Combination therapy of arthritis with tranilast.
8 GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential. Expert Rev Clin Immunol. 2015 Apr;11(4):457-65.
9 Clinical pipeline report, company report or official report of Morphotek.